Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
Through the use of robotic assisted orthopaedic surgeries, the success rate is close to 98%
There is a pressing need for continuous improvement and innovation in food safety systems to keep pace with emerging food trends and habits
This product would be manufactured at Lupin's Nagpur facility in India
If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU
Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
KEYTRUDA plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
Subscribe To Our Newsletter & Stay Updated
